CORRESP Filing
Regen BioPharma Inc
Date: Sept. 4, 2025 · CIK: 0001589150 · Accession: 0001641172-25-026585
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-12654
Letter
Via Edgar Securities and Exchange Commission Washington, D.C. 20549-7410 Attn: Tyler Howes September 4, 2025
Re: Regen BioPharma, Inc. Offering Statement on Form 1-A Filed August 29, 2025 File No.: 024-12654
Dear Mr. Howes
Regen Biopharma, Inc. (the "Company") hereby requests qualification of the above-referenced offering statement at 9:30 a.m., Eastern Time, on September 5, 2025 or as soon thereafter as is practicable.
In connection with the foregoing request, the Company hereby confirms and acknowledges that:
1. should the Commission or the staff, acting pursuant to delegated authority, qualify the filing, it does not foreclose the Commission from taking any action with respect to the filing;
2. the action of the Commission or the staff, acting pursuant to delegated authority, in qualifying the filing, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
3. the Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
If you should require any additional information or clarification, please do not hesitate to contact me.
Very
truly yours,
/s/
David R.Koos
Show Raw Text
CORRESP 1 filename1.htm Via Edgar Securities and Exchange Commission 100 F. Street, NE Washington, D.C. 20549-7410 Attn: Tyler Howes September 4, 2025 Re: Regen BioPharma, Inc. Offering Statement on Form 1-A Filed August 29, 2025 File No.: 024-12654 Dear Mr. Howes Regen Biopharma, Inc. (the "Company") hereby requests qualification of the above-referenced offering statement at 9:30 a.m., Eastern Time, on September 5, 2025 or as soon thereafter as is practicable. In connection with the foregoing request, the Company hereby confirms and acknowledges that: 1. should the Commission or the staff, acting pursuant to delegated authority, qualify the filing, it does not foreclose the Commission from taking any action with respect to the filing; 2. the action of the Commission or the staff, acting pursuant to delegated authority, in qualifying the filing, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and 3. the Company may not assert staff comments and/or qualification as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. If you should require any additional information or clarification, please do not hesitate to contact me. Very truly yours, /s/ David R.Koos David R. Koos, Chairman & CEO